We are analyzing https://link.springer.com/article/10.1007/s11095-007-9460-8.

Title:
Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology | Pharmaceutical Research
Description:
Purpose The effective delivery of short interfering RNA (siRNA) to brain following intravenous administration requires the development of a delivery system for transport of the siRNA across the brain capillary endothelial wall, which forms the blood–brain barrier in vivo. Methods siRNA was delivered to brain in vivo with the combined use of a receptor-specific monoclonal antibody delivery system, and avidin–biotin technology. The siRNA was mono-biotinylated on either terminus of the sense strand, in parallel with the production of a conjugate of the targeting MAb and streptavidin. Results Rat glial cells (C6 or RG-2) were permanently transfected with the luciferase gene, and implanted in the brain of adult rats. Following the formation of intra-cranial tumors, the rats were treated with a single intravenous injection of 270 μg/kg of biotinylated siRNA attached to a transferrin receptor antibody via a biotin–streptavidin linker. The intravenous administration of the siRNA caused a 69–81% decrease in luciferase gene expression in the intracranial brain cancer in vivo. Conclusions Brain delivery of siRNA following intravenous administration is possible with siRNAs that are targeted to brain with the combined use of receptor specific antibody delivery systems and avidin–biotin technology.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Shopping

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, google, scholar, pubmed, cas, brain, pardridge, gene, sirna, delivery, vivo, zhang, receptor, rna, intravenous, targeting, boado, bloodbrain, barrier, antibody, cancer, research, interfering, monoclonal, small, privacy, cookies, content, technology, cells, access, rnas, human, res, ther, usa, publish, search, avidinbiotin, administration, methods, transferrin, expression, silencing, interference, physiol, analysis, data, information, log,

Topics {✒️}

month download article/chapter anti-transferrin receptor antibody induce sequence-specific silencing primate blood–brain barrier human insulin receptor brain drug-targeting technology pubmed google scholar transferrin receptor antibody blood–brain barrier sirna-induced caveolin-1 knockdown related subjects avidin–biotin technology small interfering rna nucleic acid analogue monoclonal antibody short interfering rna rna interference transferrin receptor serves blood flow metab privacy choices/manage cookies full article pdf luciferase gene expression rna affinity vector-mediated delivery small interfering rnas human brain capillaries effective brain targeting cerebral microvascular permeability short hairpin rnas google scholar imaging brain amyloid single intravenous injection receptor targeting biotin–streptavidin linker european economic area intra-cranial tumors experimental neuro-oncology central nervous systemnature intravenous rnai conditions privacy policy intravenous administration requires article xia gene expression abeta peptide radiopharmaceutical somatic mammalian cells cultured mammalian cells biotin delivery gene silencing intracranial brain cancer improve sirna specificity

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology
         description:The effective delivery of short interfering RNA (siRNA) to brain following intravenous administration requires the development of a delivery system for transport of the siRNA across the brain capillary endothelial wall, which forms the blood–brain barrier in vivo. siRNA was delivered to brain in vivo with the combined use of a receptor-specific monoclonal antibody delivery system, and avidin–biotin technology. The siRNA was mono-biotinylated on either terminus of the sense strand, in parallel with the production of a conjugate of the targeting MAb and streptavidin. Rat glial cells (C6 or RG-2) were permanently transfected with the luciferase gene, and implanted in the brain of adult rats. Following the formation of intra-cranial tumors, the rats were treated with a single intravenous injection of 270 μg/kg of biotinylated siRNA attached to a transferrin receptor antibody via a biotin–streptavidin linker. The intravenous administration of the siRNA caused a 69–81% decrease in luciferase gene expression in the intracranial brain cancer in vivo. Brain delivery of siRNA following intravenous administration is possible with siRNAs that are targeted to brain with the combined use of receptor specific antibody delivery systems and avidin–biotin technology.
         datePublished:2007-10-11T00:00:00Z
         dateModified:2007-10-11T00:00:00Z
         pageStart:2309
         pageEnd:2316
         sameAs:https://doi.org/10.1007/s11095-007-9460-8
         keywords:
            avidin
            biotin
            blood–brain barrier
            monoclonal antibody
            RNA interference
            Pharmacology/Toxicology
            Pharmacy
            Biochemistry
            general
            Medical Law
            Biomedical Engineering and Bioengineering
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig5_HTML.gif
         isPartOf:
            name:Pharmaceutical Research
            issn:
               1573-904X
               0724-8741
            volumeNumber:24
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chun-Fang Xia
               affiliation:
                     name:UCLA
                     address:
                        name:Department of Medicine, UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yufeng Zhang
               affiliation:
                     name:ArmaGen Technologies, Inc.
                     address:
                        name:ArmaGen Technologies, Inc., Santa Monica, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yun Zhang
               affiliation:
                     name:UCLA
                     address:
                        name:Department of Medicine, UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:ArmaGen Technologies, Inc.
                     address:
                        name:ArmaGen Technologies, Inc., Santa Monica, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ruben J. Boado
               affiliation:
                     name:UCLA
                     address:
                        name:Department of Medicine, UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:ArmaGen Technologies, Inc.
                     address:
                        name:ArmaGen Technologies, Inc., Santa Monica, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William M. Pardridge
               affiliation:
                     name:UCLA
                     address:
                        name:Department of Medicine, UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology
      description:The effective delivery of short interfering RNA (siRNA) to brain following intravenous administration requires the development of a delivery system for transport of the siRNA across the brain capillary endothelial wall, which forms the blood–brain barrier in vivo. siRNA was delivered to brain in vivo with the combined use of a receptor-specific monoclonal antibody delivery system, and avidin–biotin technology. The siRNA was mono-biotinylated on either terminus of the sense strand, in parallel with the production of a conjugate of the targeting MAb and streptavidin. Rat glial cells (C6 or RG-2) were permanently transfected with the luciferase gene, and implanted in the brain of adult rats. Following the formation of intra-cranial tumors, the rats were treated with a single intravenous injection of 270 μg/kg of biotinylated siRNA attached to a transferrin receptor antibody via a biotin–streptavidin linker. The intravenous administration of the siRNA caused a 69–81% decrease in luciferase gene expression in the intracranial brain cancer in vivo. Brain delivery of siRNA following intravenous administration is possible with siRNAs that are targeted to brain with the combined use of receptor specific antibody delivery systems and avidin–biotin technology.
      datePublished:2007-10-11T00:00:00Z
      dateModified:2007-10-11T00:00:00Z
      pageStart:2309
      pageEnd:2316
      sameAs:https://doi.org/10.1007/s11095-007-9460-8
      keywords:
         avidin
         biotin
         blood–brain barrier
         monoclonal antibody
         RNA interference
         Pharmacology/Toxicology
         Pharmacy
         Biochemistry
         general
         Medical Law
         Biomedical Engineering and Bioengineering
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-007-9460-8/MediaObjects/11095_2007_9460_Fig5_HTML.gif
      isPartOf:
         name:Pharmaceutical Research
         issn:
            1573-904X
            0724-8741
         volumeNumber:24
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chun-Fang Xia
            affiliation:
                  name:UCLA
                  address:
                     name:Department of Medicine, UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yufeng Zhang
            affiliation:
                  name:ArmaGen Technologies, Inc.
                  address:
                     name:ArmaGen Technologies, Inc., Santa Monica, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yun Zhang
            affiliation:
                  name:UCLA
                  address:
                     name:Department of Medicine, UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:ArmaGen Technologies, Inc.
                  address:
                     name:ArmaGen Technologies, Inc., Santa Monica, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ruben J. Boado
            affiliation:
                  name:UCLA
                  address:
                     name:Department of Medicine, UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:ArmaGen Technologies, Inc.
                  address:
                     name:ArmaGen Technologies, Inc., Santa Monica, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William M. Pardridge
            affiliation:
                  name:UCLA
                  address:
                     name:Department of Medicine, UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Pharmaceutical Research
      issn:
         1573-904X
         0724-8741
      volumeNumber:24
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:UCLA
      address:
         name:Department of Medicine, UCLA, Los Angeles, USA
         type:PostalAddress
      name:ArmaGen Technologies, Inc.
      address:
         name:ArmaGen Technologies, Inc., Santa Monica, USA
         type:PostalAddress
      name:UCLA
      address:
         name:Department of Medicine, UCLA, Los Angeles, USA
         type:PostalAddress
      name:ArmaGen Technologies, Inc.
      address:
         name:ArmaGen Technologies, Inc., Santa Monica, USA
         type:PostalAddress
      name:UCLA
      address:
         name:Department of Medicine, UCLA, Los Angeles, USA
         type:PostalAddress
      name:ArmaGen Technologies, Inc.
      address:
         name:ArmaGen Technologies, Inc., Santa Monica, USA
         type:PostalAddress
      name:UCLA
      address:
         name:Department of Medicine, UCLA, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chun-Fang Xia
      affiliation:
            name:UCLA
            address:
               name:Department of Medicine, UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Yufeng Zhang
      affiliation:
            name:ArmaGen Technologies, Inc.
            address:
               name:ArmaGen Technologies, Inc., Santa Monica, USA
               type:PostalAddress
            type:Organization
      name:Yun Zhang
      affiliation:
            name:UCLA
            address:
               name:Department of Medicine, UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:ArmaGen Technologies, Inc.
            address:
               name:ArmaGen Technologies, Inc., Santa Monica, USA
               type:PostalAddress
            type:Organization
      name:Ruben J. Boado
      affiliation:
            name:UCLA
            address:
               name:Department of Medicine, UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:ArmaGen Technologies, Inc.
            address:
               name:ArmaGen Technologies, Inc., Santa Monica, USA
               type:PostalAddress
            type:Organization
      name:William M. Pardridge
      affiliation:
            name:UCLA
            address:
               name:Department of Medicine, UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medicine, UCLA, Los Angeles, USA
      name:ArmaGen Technologies, Inc., Santa Monica, USA
      name:Department of Medicine, UCLA, Los Angeles, USA
      name:ArmaGen Technologies, Inc., Santa Monica, USA
      name:Department of Medicine, UCLA, Los Angeles, USA
      name:ArmaGen Technologies, Inc., Santa Monica, USA
      name:Department of Medicine, UCLA, Los Angeles, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(115)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.96s.

LINK . SPRINGER . COM {}